Skip to main content
Pfizer10-Q: Bookings decline

Paxlovid Q3 revenue drops 63% operationally to $449 million on lower COVID-19 infections

Source: Autobound Signal API · 104 signals tracked for Pfizer · updated

Get Pfizer's live signals in Claude or ChatGPT, or by API

AskWhat changed at Pfizer this week? Use Autobound signals for pfizer.com.

What happened

Pfizer reported a 63% operational decline in worldwide Paxlovid revenue to $449 million for the third quarter of 2026, driven by lower COVID-19 infection rates across the U.S. and international markets. This persistent post-pandemic revenue contraction highlights Pfizer's ongoing commercial pivot toward non-COVID biopharma growth.

Source

SEC EDGARNov 3, 2026

Quarterly report (Form 10-Q)

Pfizer 10-Q for Quarter ended Sep 27, 2026

Filing excerpt

QTD decline primarily driven by lower COVID-19 infections across the U.S. and international markets, partially offset by timing of government purchases in certain emerging markets.

sec.gov/Archives/edgar/data/78003/000007800326000127/pfe-20260927.htmRead the full source

Other signals in this filing (3)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Bookings decline

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Sep 27, 2026
Fiscal year end
09/27
Filed
Nov 3, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Percent
-63% (Paxlovid QTD operational revenue decline)

Details

CIK
78003
Accession number
0000078003-26-000127
Timeframe
Current quarter
Quarter
Q3
Filing year
2026
Period end date
Sep 27, 2026
Why it matters
Sales effectiveness tools
Signal category
Revenue

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
75%
Sentiment
Negative
Detected
Nov 10, 2026
signal_type
sec-10q
signal_subtype
bookingsDecline

Use this data

Get every 10-Q signal for Pfizer and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Pfizer this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/db36a38d-ee50-4bb6-b471-b60404a4301c returns this record as JSON. POST /v1/companies/enrich returns every signal for pfizer.com.

{
  "signal_id": "db36a38d-ee50-4bb6-b471-b60404a4301c",
  "signal_type": "sec-10q",
  "signal_subtype": "bookingsDecline",
  "detected_at": "2026-11-10T08:02:41.191+00:00",
  "company": {
    "name": "Pfizer",
    "domain": "pfizer.com"
  },
  "data": {
    "detail": "Pfizer reported a 63% operational decline in worldwide Paxlovid revenue to $449 million for the third quarter of 2026, driven by lower COVID-19 infection rates across the U.S. and international markets. This persistent post-pandemic revenue contraction highlights Pfizer's ongoing commercial pivot toward non-COVID biopharma growth.",
    "metrics": {
      "pct": -0.63,
      "timeframe": "current_quarter",
      "pct_context": "Paxlovid QTD operational revenue decline",
      "dollar_context": "Paxlovid worldwide revenue in Q3 2026"
    },
    "quarter": "Q3",
    "summary": "Paxlovid Q3 revenue drops 63% operationally to $449 million on lower COVID-19 infections",
    "excerpts": "QTD decline primarily driven by lower COVID-19 infections across the U.S. and international markets, partially offset by timing of government purchases in certain emerging markets.",
    "relevance": 0.75,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/pfe-20260927.htm",
    "filing_date": "2026-11-03",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "09/27",
    "period_end_date": "2026-09-27",
    "sales_relevance": "Sales effectiveness tools",
    "signal_category": "revenue",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.